InvivoChem Cat #:V10435CAS #:68392-35-8Purity >=98%Description: Afimoxifene (4-hydroxytamoxifen), an active metabolite of tamoxifen with both estrogenic and anti-estrogenic effects, is a SERM (selective estrogen receptor modulator). Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia. A study in France on 55 women showed that rubbing afimoxifene on the skin was as good as tamoxifen tablets at slowing breast cancer growth. A US trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen. ( //en.wikipedia.org/wiki/Afimoxifene).
References: Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008 Mar; 7(3):670-8. PubMed PMID: 18347152.